{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-000411","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.803537+00:00","generated_at":"2026-05-28T03:42:23.587727+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"ADC Therapeutics releases preliminary 2024 ZYNLONTA sales and expense data at JPM conference","bullets":["Preliminary ZYNLONTA net sales and FY2024 expenses disclosed at JPMorgan Healthcare Conference; no specific figures in filing.","Forward-looking statements reference expected cash runway into mid-2026 and potential to grow ZYNLONTA revenue.","Presentation highlights pipeline including LOTIS 5, LOTIS 7, ADCT-602, and exatecan-based solid tumor platform.","ZYNLONTA is approved for relapsed/refractory large B-cell lymphoma after two prior therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-000411","json":"https://secwatch.observer/filing/0000950103-25-000411.json","markdown":"https://secwatch.observer/filing/0000950103-25-000411.md","text":"https://secwatch.observer/filing/0000950103-25-000411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325000411/0000950103-25-000411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325000411/dp223356_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:42:23.587727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}